Sobetirome

SKU: orb1301898

Description

Sobetirome

Research Area

Metabolism Research

Key Properties

• CAS Number: 211110-63-3
• MW: 328.4
• Purity: 98.08%
• Formula: C₂₀H₂₄O₄
• SMILES: CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O
• Target: Thyroid hormone receptor(THR)
• Solubility: Ethanol:30 mg/mL (91.35 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.09 mM);DMSO:145 mg/mL (441.53 mM)

Bioactivity

• Target IC50:
  TRα1:0.58 μM (EC50)|TRβ1:0.16 μM (EC50)
• In Vivo:
  Four weeks following injection, mice were fed 5 mg/kgSobetirome or basal diet for 10 or 21 days. Treatment withSobetirome for 10 or 21 days led to a significant reduction in tumor burden. obetirome treatment reduced serum cholesterol levels by 25% and serum triglycerides by 75% in chow-fed mice and also attenuated diet-induced hypercholesterolemia. obetirome (50 or 100 mug/100 g body weight) strongly stimulates rat hepatocyte proliferation in the absence of tissue injury.Sobetirome also induced massive pancreatic cell proliferation .
• In Vitro:
  GC-1 was designed to bind selectively to TRβ (EC50: 0.58 μM for TRα-1, 0.16 μM for TRβ-1) the thyromimetic agent GC-1 induces hepatocyte proliferation via Wnt/β-catenin signaling and may promote regeneration In both acute and chronic liver insufficiencies.
• Animal Research:
  Briefly, 20 μg of a pT3-EF5α-hMet-V5 and pT3-EF5α-S45Y-β-catenin-Myc combination along wit the transposase in a ratio of 25:1 were diluted in 2 ml of normal saline (0.9% NaCl), filtered through a 0.22 μM filter, and injected int the lateral tail vein of 23 FVB mice that were around 6 weeks old, in 5 to 7 seconds. These mice are referred henceforth as hMet-mutant-β-catenin mice. Four weeks after injection, hMet-mutant-β-catenin mice were andomized into two groups. One group was kept on a basal diet (n = 12), and a Other group was switched to a GC-1–supplemented diet (5 mg/kg of diet) (n = 11). Animals on control diet were sacrificed at either 21 days (n = 8) or 10 days (n = 4) after initiation o the diet. Similarly, animals o the GC-1 diet were sacrificed at either 21 days (n = 7) or 10 days (n = 4) after initiation o the diet the animals were given access to food and water ad libitum with a 12 hour light/dark daily cycle. One intraperitoneal injection of bromodeoxyuridine (BrdU) was performed on day 9 during 10 days of GC-1 or basal diet treatment, and livers were Harvested 24 hours later.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

GC 1, GC1, GC-1, IACS 010759, IACS010759, IACS-010759, inhibit, Inhibitor, Sobetirome, TRβ, THR, QRX 431, QRX431, QRX-431, Thyroidhormonereceptor(THR), Thyroidhormonereceptor, Thyroid Hormone Receptor, Thyroid hormone receptor, Thyroid hormone receptor(THR)

Compound Identifiers

PubChem CID

9862248